Qritive inks multi-year contracts for AI pathology adoption in India

By leveraging the power of artificial intelligence, these institutions are enhancing diagnostic accuracy, improving operational efficiency, and ultimately advancing patient care

Qritive, provider of AI solutions for pathology labs worldwide has announced its partnership with three diagnostic centres and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute (RGCI) and CŌRE Diagnostics. These institutions have embraced Pantheon Image Management System (IMS) and Qritive’s AI products.

By leveraging the power of artificial intelligence, these institutions are enhancing diagnostic accuracy, improving operational efficiency, and ultimately advancing patient care.

Commenting on the partnership, Surendran Chemmenkottil, CEO, Metropolis Healthcare, stated, “As we embark on this transformative journey with Qritive, we are enthusiastic about the immense potential it holds for advancing our capabilities in pathology. The integration of Qritive’s AI-powered platform into our workflows signifies a revolutionary step in enhancing precision, timeliness, and personalised diagnosis. This collaboration reinforces our commitment to setting a new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection.”

Bruno Occhipinti, CEO, Qritive said, Qritive is proud to have the opportunity to work alongside such forward-looking healthcare institutions, seizing the power of AI to improve patient outcomes and concurrently enhance the life of their pathologists. Our whole team is eager to showcase how deep tech will support clinicians and contribute to “closing the gap” in cancer care, meeting the aspirations of the World Cancer Day of February 4^th.”

Dinesh Chauhan, CEO, CŌRE Diagnostics said, We’re thrilled to partner with Qritive, integrating their advanced AI solutions into our pathology workflow at CŌRE Diagnostics. This collaboration will strengthen our diagnostic precision, resulting in improved patient outcomes, and reaffirm our dedication to delivering excellence in clinical care. The collaboration also has the potential to lead to the development of new AI services for the diagnosis of rare diseases.”

Dr Gurudutt Gupta, HOD Pathology, Rajiv Gandhi Cancer Institute Research Centre said, “Qritive’s IMS and AI modules have enhanced our pathology practice at RGCI. With efficient identification of concerning areas and precise grading, integrating these tools has enhanced our workflow and diagnostic precision, offering significant benefits to our practice.”